Division of Nephrology and Hypertension Archives
May. 2, 2019—The American Society of Gene and Cell Therapy (ASGCT) has appointed Matthew Wilson, MD, PhD, associate professor of Medicine in Vanderbilt’s Division of Nephrology and Hypertension, to its board of directors. Beginning in May 2019, Wilson will serve a three-year term as an at-large director.
Jun. 28, 2018—Jun. 28, 2018—T. Alp Ikizler, MD, an internationally known expert on the nutritional and metabolic aspects of kidney disease, will succeed Raymond Harris, MD, as director of the Department of Medicine’s Division of Nephrology and Hypertension in the Vanderbilt University School of Medicine effective July 1.
Mar. 15, 2018—New research by Vanderbilt nephrologists highlights potential barriers that may prevent black Americans from being screened for kidney disease.
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Aug. 31, 2017—Vanderbilt University Medical Center (VUMC) is studying the safety of a possible treatment for diabetic kidney disease that would delay or prevent the need for kidney replacement such as dialysis.
Sep. 17, 2015—The initial results of a landmark clinical trial sponsored by the National Institutes of Health (NIH) indicate lowering systolic blood pressure below a commonly recommended target significantly reduces rates of cardiovascular events and lowers risk of death in a group of adults 50 years and older.